<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350817</url>
  </required_header>
  <id_info>
    <org_study_id>I10004</org_study_id>
    <nct_id>NCT01350817</nct_id>
  </id_info>
  <brief_title>Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer</brief_title>
  <acronym>TARSEQ</acronym>
  <official_title>Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2 arms study will compare the efficacy and safety of treatment with sequential erlotinib
      plus docetaxel therapy versus docetaxel alone as second line treatment in patients with
      recurrent non-small cell lung cancer. Patients will be randomized to receive in group
      1(experimental arm): docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per
      os d2-d16 and group 2 (control arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.

      The anticipated time on study treatment is until disease progression. Target sample size is
      156.

      The main of this study is to determine the relevance of the association sequential erlotinib
      and docetaxel in terms of progression-free survival .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the patient will be randomized in group 1(experimental arm): docetaxel :75
      mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16 and group 2 (control arm):
      docetaxel :75 mg/m² IV day 1 every 3 weeks.

      Assessment during treatment: Physical examination, ECG,: every 3 weeks, laboratory tests:
      weekly, every 3 weeks pulmonary X-ray .The CT scans:. Measurable targets are assessed by
      RECIST compared to the beginning of treatment: at 6 weeks (day 42 EVA 2), 12 weeks (D84 EVA
      3), 15 weeks (D105 EVA 4: Evaluation of the SSP) and then every 6 weeks until progression.

      Quality of life will be assessed Day 42 then every 6 weeks during chemotherapy, Tolerability
      will be assessed at each visit based on CTC v4.0 criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival at 15 weeks.</measure>
    <time_frame>at 15 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free survival at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities and feasibility</measure>
    <time_frame>15 Weeks</time_frame>
    <description>To assess toxicities and feasibility in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib + docetaxel</intervention_name>
    <description>docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16</description>
    <arm_group_label>Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel :75 mg/m² IV day 1 every 3 weeks.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven NSCLC (

          -  Mutational status of EGFR : wild type or unknown

          -  Stage IV disease with cytologic or histologic documentation in patients with a single
             easily accessible metastasis or metastatic relapses in a non irradiated region from a
             primary tumor treated with surgery or radiotherapy (with cytologic or histologic
             documentation of relapse)

          -  Presence of at least one measurable target lesion (one dimension) in a non irradiated
             region (at least 10 mm on spiral computed tomography).

          -  Age ≥ 18 years

          -  Performance status 0,1,2 exception : age &gt; 74 years only PS 0 or 1

          -  Normal hepatic function

          -  Normal renal function

          -  Normal calcemia

          -  Normal haematological function

          -  Life expectancy &gt; 12 weeks.

          -  Women of child bearing potential must use effective contraception.

          -  Men might be surgically sterile or accept to use an effective contraceptive procedure
             during and until 6 months after the treatment.

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

          -  PS &gt; 2, exception : age &gt; 74 years only PS ≥ 2

          -  Presence of another cancer

          -  Previous treatment with an anti egfr agent or docetaxel

          -  QT prolongation (&gt;470 ms)

          -  Uncontrolled arterial hypertension.

          -  Concurrent radiotherapy, except for palliative bone irradiation.

          -  Stroke less than 6 months before study entry.

          -  Psychiatric or neurological disorders preventing the patient from understanding the
             nature of the trial

          -  Uncontrolled infection.

          -  Caval syndrome

          -  Other organic disorders preventing inclusion in the trial

          -  Malabsorption syndrome

          -  Allergy to erlotinib or one of its constituents

          -  Allergy to docetaxel or one of its constituents

          -  Pregnancy and breast-feeding

          -  Surgery less than two months before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Vergnengre, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie, CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie; Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Centre Hospitalier</name>
      <address>
        <city>Beauvais</city>
        <zip>60 021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Charleville Mezière</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie ; Centre hospitalier</name>
      <address>
        <city>Charleville-Mezieres</city>
        <zip>08 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Centre Hospitalier</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Gap</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pathologie Respiratoire du CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département des Maladies Respiratoires ; Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital St Antoine, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie-Allergologie; Centre Hospitalier Général</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; CHG de Roanne</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pneumologique; Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie; Hôpital Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle, Service de Pneumologie</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital Nord</name>
      <address>
        <city>saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

